Note 2 - Summary of Significant Accounting Policies (Tables)
|
3 Months Ended |
Mar. 31, 2026 |
|---|
| Notes Tables |
|
| Segment Reporting [Table Text Block] |
| | For the Three Months Ended March 31, | |
| | 2026 | | 2025 | |
| | Cardiac Electrophysiology | | Private Aviation | | Total | | Total | |
| Revenues: | | | | | | | | | | | | |
| Product revenue | | | | | | | | | | | | |
| VIVO | $ | 73 | | $ | — | | $ | 73 | | $ | 15 | |
| LockeT | | 175 | | | — | | | 175 | | | 128 | |
| Total product revenues | | 248 | | | — | | | 248 | | | 143 | |
| | | | | | | | | | | | | |
| Service revenue, net | | | | | | | | | | | | |
| Luxe | | — | | | 42 | | | 42 | | | — | |
| Hops | | — | | | 142 | | | 142 | | | — | |
| Total service revenues, net | | — | | | 184 | | | 184 | | | — | |
| Total revenues | | 248 | | | 184 | | | 432 | | | 143 | |
| | | | | | | | | | | | | |
| Less: | | | | | | | | | | | | |
| Cost of revenues: | | | | | | | | | | | | |
| Cost of product revenue | | 31 | | | — | | | 31 | | | 11 | |
| Cost of service revenues | | — | | | 11 | | | 11 | | | — | |
| Total cost of revenues | | 31 | | | 11 | | | 42 | | | 11 | |
| | | | | | | | | | | | | |
| Acquired in-process research and development expense | | — | | | — | | | — | | | 119 | |
| Depreciation and amortization expense | | 367 | | | 37 | | | 404 | | | 531 | |
| Stock-based compensation expense | | 64 | | | — | | | 64 | | | 91 | |
| Salaries and benefits expense | | 810 | | | 5 | | | 815 | | | 1,314 | |
| Professional fees | | 514 | | | 142 | | | 656 | | | 727 | |
| Research and development expense | | 149 | | | — | | | 149 | | | 103 | |
| Interest income | | (2 | ) | | — | | | (2 | ) | | (18 | ) |
| Interest expense | | 103 | | | 16 | | | 119 | | | 49 | |
| Change in fair value of royalties payable due to related parties | | — | | | — | | | — | | | 1,163 | |
| Change in fair value of minority equity interest | | 2,302 | | | — | | | 2,302 | | | — | |
| Change in fair value of deferred consideration | | (2,877 | ) | | — | | | (2,877 | ) | | — | |
| Income tax benefit | | (175 | ) | | — | | | (175 | ) | | (724 | ) |
| Other segment items (1) | | 520 | | | 105 | | | 625 | | | 822 | |
| Segment net loss | | (1,558 | ) | | (132 | ) | | (1,690 | ) | | (4,045 | ) |
| | | | | | | | | | | | | |
| Reconciliation of net loss | | | | | | | | | | | | |
| Adjustments and reconciling items | | — | | | — | | | — | | | — | |
| Consolidated net loss | $ | (1,558 | ) | $ | (132 | ) | $ | (1,690 | ) | $ | (4,045 | ) |
|
| Fair Value, by Balance Sheet Grouping [Table Text Block] |
| | | | | | | March 31, 2026 | | | | | |
| | | Total | | | Level 1 | | | Level 2 | | | Level 3 | |
| Assets: | | | | | | | | | | | | | | | | |
| Cash Equivalents | | | | | | | | | | | | | | | | |
| Mutual funds | | $ | 339 | | | $ | 339 | | | $ | — | | | $ | — | |
| Money market funds | | | 66 | | | | 66 | | | | — | | | | — | |
| Total assets | | $ | 405 | | | $ | 405 | | | $ | — | | | $ | — | |
| | | | | | | | | | | | | | | | | |
| Liabilities: | | | | | | | | | | | | | | | | |
| Royalties payable due to related parties | | $ | 792 | | | $ | — | | | $ | — | | | $ | 792 | |
| Deferred consideration | | | 8,151 | | | | — | | | | — | | | | 8,151 | |
| Convertible notes payable | | | 298 | | | | — | | | | — | | | | 298 | |
| Total liabilities | | $ | 9,241 | | | $ | — | | | $ | — | | | $ | 9,241 | |
| | | | | | | December 31, 2025 | | | | | |
| | | Total | | | Level 1 | | | Level 2 | | | Level 3 | |
| Assets: | | | | | | | | | | | | | | | | |
| Cash Equivalents | | | | | | | | | | | | | | | | |
| Money market funds | | $ | 2 | | | $ | 2 | | | $ | — | | | $ | — | |
| Total assets | | $ | 2 | | | $ | 2 | | | $ | — | | | $ | — | |
| | | | | | | | | | | | | | | | | |
| Liabilities: | | | | | | | | | | | | | | | | |
| Royalties payable due to related parties | | $ | 792 | | | $ | — | | | $ | — | | | $ | 792 | |
| Convertible notes payable | | | 298 | | | | — | | | | — | | | | 298 | |
| Total liabilities | | $ | 1,090 | | | $ | — | | | $ | — | | | $ | 1,090 | |
|
| Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] |
| | | Fair Value Measurements Using Significant Unobservable Inputs (Level 3) |
| | Royalties Payable due to Related Parties | | Deferred Consideration | | | Convertible Notes Payable |
| Balance at January 1, 2026 | $ | 792 | | $ | — | | $ | 298 |
| Fair value at issuance | | — | | | 11,028 | | | — |
| Change in fair value | | — | | | (2,877) | | | — |
| Balance at March 31, 2026 | $ | 792 | | $ | 8,151 | | $ | 298 |
| | | | Fair Value Measurements Using Significant Unobservable Inputs (Level 3) |
| | | | Royalties Payable due to
Related Parties | | | Deferred Consideration | | | Convertible Notes Payable |
| Balance at January 1, 2025 | | $ | 9,213 | | $ | — | | $ | — |
| Change in fair value | | | 1,163 | | | — | | | — |
| Balance at March 31, 2025 | | $ | 10,376 | | $ | — | | $ | — |
|
| Schedule of Property, Plant and Equipment, Useful Life [Table Text Block] |
| Machinery and equipment | | | 2 - 5 years | |
| Computer hardware and software | | | 1 - 5 years | |
| LockeT animation video | | | 3 years | |
| VIVO DEMO/Clinical Systems | | | 1-5 years | |
|
| Disaggregation of Revenue [Table Text Block] |
| | | For the Three Months Ended March 31, | |
| | | 2026 | | 2025 | |
| Revenue - Product | | | | | | | |
| US | | $ | 94 | | $ | 135 | |
| Europe | | | 154 | | | 8 | |
| Total Revenue - Product | | | 248 | | | 143 | |
| | | | | | | | |
| Revenue - Services | | | | | | | |
| US | | | 184 | | | — | |
| Europe | | | — | | | — | |
| Total Revenue - Services | | $ | 184 | | $ | — | |
|
| Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block] |
| | | For the Three Months Ended March 31, | |
| | | 2026 | | 2025 | |
| Deferred revenue, beginning of period | | $ | — | | $ | — | |
| Deferred revenue assumed as part of acquisition (see Note 3) | | | 171 | | | — | |
| Revenue recognized during the period related to amounts included in the deferred revenue assumed | | | (92 | ) | | — | |
| Revenue deferred, net of revenue recognized during the period | | | 47 | | | — | |
| Deferred revenue, end of period | | $ | 126 | | $ | — | |
|
| Royalties Payable [Member] |
|
| Notes Tables |
|
| Fair Value Measurement Inputs and Valuation Techniques [Table Text Block] |
| | | | | | |
| Instrument | Valuation Technique | Unobservable Input | Input Range | |
| Royalties payable due to related parties | Discounted future cash flows | Share price | | 19.5 | % |
| Deferred consideration | If converted method | Discount for lack of marketability | | 20 | % |
|